StreetInsider.com News Articles

Form 8-K Tempest Therapeutics, For: Aug 18

Mon, 24 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260824/26968715.html

Form 8-K Tempest Therapeutics, For: Aug 18

Mon, 24 Aug 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260824/26968715.html

Form S-1 Tempest Therapeutics,

Fri, 21 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260821/26962001.html

Form S-1 Tempest Therapeutics,

Fri, 21 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260821/26962001.html

Form DEFA14A Tempest Therapeutics,

Tue, 18 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260818/26944778.html

Form DEFA14A Tempest Therapeutics,

Tue, 18 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260818/26944778.html

Form 8-K Tempest Therapeutics, For: Aug 17

Tue, 18 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260818/26944713.html

Form 8-K Tempest Therapeutics, For: Aug 17

Tue, 18 Aug 2026 16:28:00 -0400

si-local-file:///var/storage/secattach/20260818/26944713.html

Form 10-Q Tempest Therapeutics, For: Jun 30

Thu, 13 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260813/26922070.html

Form 10-Q Tempest Therapeutics, For: Jun 30

Thu, 13 Aug 2026 16:38:00 -0400

si-local-file:///var/storage/secattach/20260813/26922070.html

Form 8-K Tempest Therapeutics, For: Aug 13

Thu, 13 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260813/26922028.html

Form 8-K Tempest Therapeutics, For: Aug 13

Thu, 13 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260813/26922028.html

Form 8-K Tempest Therapeutics, For: Aug 13

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921900.html

Form 8-K Tempest Therapeutics, For: Aug 13

Thu, 13 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260813/26921900.html

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:25:00 -0400

Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027

Unveiled pipeline of next-generation in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD-7 targeted mRNA/LNP delivery approach

Appointed Drake Richey and John Yee, MD, MPH, to Board of Directors

BRISBANE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:25:00 -0400

Unveiled pipeline of next-generation in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD-7 targeted mRNA/LNP delivery approach

Appointed Drake Richey and John Yee, MD, MPH, to Board of Directors

BRISBANE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:25:00 -0400

Unveiled pipeline of next-generation in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD-7 targeted mRNA/LNP delivery approach

Appointed Drake Richey and John Yee, MD, MPH, to Board of Directors

BRISBANE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 13 Aug 2026 16:25:00 -0400

Unveiled pipeline of next-generation in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD-7 targeted mRNA/LNP delivery approach

Appointed Drake Richey and John Yee, MD, MPH, to Board of Directors

BRISBANE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq:

Form DEFA14A Tempest Therapeutics,

Tue, 28 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260728/26828135.html

Form DEFA14A Tempest Therapeutics,

Tue, 28 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260728/26828135.html

Form 8-K Tempest Therapeutics, For: Jul 27

Tue, 28 Jul 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260728/26828092.html

Form 8-K Tempest Therapeutics, For: Jul 27

Tue, 28 Jul 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260728/26828092.html

Form 8-K Tempest Therapeutics, For: Jul 17

Wed, 22 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260722/26801646.html

Form 8-K Tempest Therapeutics, For: Jul 17

Wed, 22 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260722/26801646.html

Tempest Therapeutics partners with Senlang on in vivo CAR-T candidate

Tue, 21 Jul 2026 07:02:05 -0400

Tempest Therapeutics (Nasdaq: TPST) announced a development collaboration with Hebei Senlang Biotechnology Co., Ltd. for TPST-4003, an in vivo CAR-T product candidate targeting autoimmune diseases, according to a press release issued July 21, 2026.

Under the agreement, Senlang will conduct an investigator-initiated trial of TPST-4003 in China, enrolling approximately 10 patients with myasthenia gravis or multiple sclerosis. First patient dosing is expected in the fourth quarter of 2026, with initial safety and pharmacodynamic data anticipated as early as the first half of 2027.

TPST-4003 combines CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to deplete B-cell lineages. The trial will